1114876-08-2 Usage
General Description
Methyl 3-Methylazetidine-3-carboxylate hydrochloride is a chemical compound that belongs to the class of azetidine carboxylate derivatives. It is commonly used in organic synthesis as a building block for the preparation of various pharmaceutical compounds. Methyl 3-Methylazetidine-3-carboxylate hydrochloride is formed by the esterification of 3-methylazetidine-3-carboxylic acid with methanol, followed by the addition of hydrochloric acid to form the hydrochloride salt. Methyl 3-Methylazetidine-3-carboxylate hydrochloride has potential applications in the development of new drugs and in medicinal chemistry research for the treatment of various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 1114876-08-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,4,8,7 and 6 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1114876-08:
(9*1)+(8*1)+(7*1)+(6*4)+(5*8)+(4*7)+(3*6)+(2*0)+(1*8)=142
142 % 10 = 2
So 1114876-08-2 is a valid CAS Registry Number.
1114876-08-2Relevant articles and documents
HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS
-
Page/Page column 148; 308, (2020/06/05)
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10,Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
NOVEL PYRIDINE COMPOUNDS
-
Page/Page column 172, (2008/06/13)
The present invention relates to certain novel pyridin compounds of Formula ( I ) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
